Market Overview

Acorda Launches Alexa Skill in Conjunction with MS Awareness Month


Acorda Therapeutics, Inc. (Nasdaq: ACOR)
today announced the launch of its Alexa skill, MS
Awareness Facts
, as part of the
company's activities in recognition of Multiple Sclerosis (MS) Awareness
Month. The skill allows users to ask Amazon Alexa for an MS Awareness
Fact to learn more about multiple sclerosis and find helpful information
on MS and its symptoms.

This Smart News Release features multimedia. View the full release here:

Amazon Alexa is Amazon's cloud-based voice service. Using voice
commands, users interact with Alexa, asking her for what they want, in
this case, "Alexa, start MS Awareness." Alexa will randomly select from
one of almost 50 tips and facts about MS, and read it aloud to the user.

"We're proud to be at the forefront of using this new technology to
connect with patients," said Michael Russo, Executive Director,
Corporate Digital Strategy & Innovation. "Education is an important
component of each person's fight against multiple sclerosis. As we move
towards becoming an increasingly digital society, it's important that we
provide solutions that match the way people live and work, and in this
case that means voice search."

The MS Awareness Facts skill leverages content from the company's
award-winning MS
™ app. In addition to the skill, Acorda has also created a team
on Charity
, a free app for Android
or iPhone.
Charity Miles allows users to raise money for charity by walking,
running, or biking. Users can download the app and join Acorda's team by
searching for #MSAwareness; Acorda team members may elect an MS charity
as the recipient of funds raised.

About MS Awareness Month

Throughout the month of March, advocacy organizations such as the
National MS Society, the MS Association of America, the MS Foundation
campaign to expand knowledge, understanding and support of multiple

About Multiple Sclerosis

Multiple sclerosis (MS) is a chronic, usually progressive disease in
which the immune system attacks and degrades the function of nerve
fibers in the brain and spinal cord by destroying myelin (a process
known as demyelination) and eventually the nerve fibers themselves.
Myelin is a fatty layer of membranes that insulates nerves, facilitating
the transmission of electrical impulses through nerve pathways that
control all neurological functions. In people with MS, disruption in
neurological function often leads to impairments in movement,
bowel/bladder function, vision and sexual function. More than 400,000
people in the U.S. and nearly 2.5 million people worldwide are living
with MS.

About Acorda Therapeutics

Founded in 1995, Acorda Therapeutics is a biotechnology company focused
on developing therapies that restore function and improve the lives of
people with neurological disorders.

Acorda has an industry leading pipeline of novel neurological therapies
addressing a range of disorders, including Parkinson's disease, migraine
and multiple sclerosis. Acorda markets three FDA-approved therapies,
including AMPYRA® (dalfampridine) Extended Release Tablets,
10 mg.Acorda, Acorda Therapeutics, Ampyra and MS Self are registered
trademarks of Acorda Therapeutics Inc.

For more information, please visit the Company's website at:

Forward-Looking Statement

This press release includes forward-looking statements. All statements,
other than statements of historical facts, regarding management's
expectations, beliefs, goals, plans or prospects should be considered
forward-looking. These statements are subject to risks and uncertainties
that could cause actual results to differ materially, including: the
ability to realize the benefits anticipated from the Biotie and Civitas
transactions, among other reasons because acquired development programs
are generally subject to all the risks inherent in the drug development
process and our knowledge of the risks specifically relevant to acquired
programs generally improves over time; the ability to successfully
integrate Biotie's operations and Civitas' operations, respectively,
into our operations; we may need to raise additional funds to finance
our expanded operations and may not be able to do so on acceptable
terms; our ability to successfully market and sell Ampyra
(dalfampridine) Extended Release Tablets, 10 mg in the U.S.; third party
payers (including governmental agencies) may not reimburse for the use
of Ampyra or our other products at acceptable rates or at all and may
impose restrictive prior authorization requirements that limit or block
prescriptions; the risk of unfavorable results from future studies of
Ampyra or from our other research and development programs, including
CVT-301 or any other acquired or in-licensed programs; we may not be
able to complete development of, obtain regulatory approval for, or
successfully market CVT-301, any other products under development, or
the products that we will acquire when we complete the Biotie
transaction; the occurrence of adverse safety events with our products;
delays in obtaining or failure to obtain and maintain regulatory
approval of or to successfully market Fampyra outside of the U.S. and
our dependence on our collaborator Biogen in connection therewith;
competition; failure to protect our intellectual property, to defend
against the intellectual property claims of others or to obtain third
party intellectual property licenses needed for the commercialization of
our products; and failure to comply with regulatory requirements could
result in adverse action by regulatory agencies.

These and other risks are described in greater detail in our filings
with the Securities and Exchange Commission. We may not actually achieve
the goals or plans described in our forward-looking statements, and
investors should not place undue reliance on these statements.
Forward-looking statements made in this press release are made only as
of the date hereof, and we disclaim any intent or obligation to update
any forward-looking statements as a result of developments occurring
after the date of this press release.

View Comments and Join the Discussion!